Search results for " biopharmaceuticals"
Article
The Affordable Care Act's Impact on Innovation in Biopharma
• Generate evidence that delivers the net benefit of biopharmaceuticals in the broadest “real world” context (i.e., clinical, economic, quality of life, and productivity measures) in addition to gener…
Article
Roadmap Leads to Innovative Biomanufacturing Strategies
Evolving capacity needs
BioPharm: How would the Biomanufacturing Technology Roadmap remain relevant as the manufacturing technology and capacity needs in the biopharmaceuticals industry continue t…
Article
Platform Approach Speeds Process Development
By Harald Bradl, Jan Bechmann, Benedikt Greulich, Markus Michael Mueller, Patrick Schulz, Thomas Wucherpfennig
Commercial production of complex biopharmaceuticals such as recombinant monoclonal an…
Article
The Future of Biopharma
In response, most large pharmaceutical companies are now devoting increasing development efforts on biopharmaceuticals rather than small molecule drugs. Some are now spending 40% or more of their R&D …
Article
Understanding Validation and Technical Transfer, Part 2
Understanding Validation and Technical Transfer, Part 2
A validation plan developed to support a process unrelated to bio-pharmaceutical manufacture is applied to biopharmaceutical processes and sys…
Article
Securing the Single-Use Supply Chain
Dual sourcing is one of many possible solutions to securing the supply chain.
Single-use systems (SUS) have become established in biopharmaceutical drug development. As confidence in the technol…
Article
Setting Standards for Biotech Therapeutics in India
The biopharmaceuticals market has witnessed the fastest growth in the 2013 financial year as compared to other biotech markets (e.g., Bio-Agri, Bio-Services, and Bio-Informatics).
Growth in this s…
Article
Brazil Emerges as Global Biopharm Collaborator
“Our increase of the biopharmaceuticals market share is mainly a result of public investments for the government’s health system,” Guimarães told BioPharm International. The government is acting as a …
Article
Modeling the Degradation of mAb Therapeutics
This is particularly true for monoclonal antibodies (mAbs), which account for most commercial biopharmaceuticals today. Both physical effects such as aggregation and chemical modifications (e.g., frag…
Article
Process Development: What May Lie Ahead in 2018?
2018 is shaping up to be an interesting year in the world of biopharmaceuticals. What have 2017 developments taught us, and what may lie ahead for biopharmaceutical drug developers and process engin…